9R5 Stock Overview
Provides diagnostic health care products and services in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Spermosens AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0004 |
| 52 Week High | SEK 0.08 |
| 52 Week Low | SEK 0.0002 |
| Beta | -0.24 |
| 11 Month Change | -33.33% |
| 3 Month Change | -83.33% |
| 1 Year Change | -99.09% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9R5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -99.1% | -17.2% | 8.2% |
Return vs Industry: 9R5 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 9R5 underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 9R5 volatility | |
|---|---|
| 9R5 Average Weekly Movement | 55.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 9R5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9R5's weekly volatility has increased from 43% to 55% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 3 | Tore Duvold | www.spermosens.com |
Spermosens AB provides diagnostic health care products and services in Sweden. The company offers male infertility fertility diagnostics and fertility treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding.
Spermosens AB Fundamentals Summary
| 9R5 fundamental statistics | |
|---|---|
| Market cap | €320.60k |
| Earnings (TTM) | -€846.80k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs 9R5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9R5 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 9.74m |
| Earnings | -SEK 9.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.8% |
How did 9R5 perform over the long term?
See historical performance and comparison